



**Cameroon**

**Country Operational Plan**

**FY 2015**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source	Applied Pipeline
	GAP	GHP-State	GHP-USAID	Total	
DOD		1,740,867		<b>1,740,867</b>	40,000
HHS/CDC	575,119	21,785,905		<b>22,361,024</b>	0
PC		995,753		<b>995,753</b>	0
State		320,000		<b>320,000</b>	0
USAID		4,001,396	1,500,000	<b>5,501,396</b>	5,290,960
<b>Total</b>	<b>575,119</b>	<b>28,843,921</b>	<b>1,500,000</b>	<b>30,919,040</b>	<b>5,330,960</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency					On Hold Amount	Total
	State	DOD	HHS/CDC	PC	USAID		
HBHC		246,782	1,300,874	125,000	998,232	0	<b>2,670,888</b>
HKID				64,093	603,656	0	<b>667,749</b>
HLAB		4,500	836,762		0	0	<b>841,262</b>
HMBL			226,391		0	0	<b>226,391</b>
HTXS		1,080,142	10,545,110		444,813	0	<b>12,070,065</b>
HVCT		180,185	1,603,547	1,517	172,890	0	<b>1,958,139</b>
HVMS	290,545	68,399	3,698,792	546,620	385,410	0	<b>4,989,766</b>
HVOP		19,400		253,466	1,025,508	0	<b>1,298,374</b>
HVSI	29,455	1,297	525,333	5,057	391,930	0	<b>953,072</b>
HVTB		37,812	486,220		9,811	0	<b>533,843</b>
MTCT		57,938	1,002,263		318,250	0	<b>1,378,451</b>
OHSS		12,000	295,955		921,756	0	<b>1,229,711</b>
PDCS		30,162	1,042,739		229,140	0	<b>1,302,041</b>
PDTX		2,250	797,038			0	<b>799,288</b>
	<b>320,000</b>	<b>1,740,867</b>	<b>22,361,024</b>	<b>995,753</b>	<b>5,501,396</b>	<b>0</b>	<b>30,919,040</b>





## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	2,421,472	0
HKID	611,291	0
HVTB	499,688	0
PDCS	1,240,360	0
<b>Total Technical Area Planned Funding:</b>	<b>4,772,811</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	621,232	0
HVSI	750,744	0
OHSS	1,005,058	0
<b>Total Technical Area Planned Funding:</b>	<b>2,377,034</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HMBL	200,000	0
HVCT	1,903,994	0
HVOP	1,169,503	0
MTCT	1,193,305	0
<b>Total Technical Area Planned Funding:</b>	<b>4,466,802</b>	<b>0</b>

#### Technical Area: Treatment



Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	11,736,492	0
PDTX	682,676	0
<b>Total Technical Area Planned Funding:</b>	<b>12,419,168</b>	<b>0</b>

## Technical Area Summary Indicators and Targets

Indicator Number	Label	2015	2016
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)		43,378
	Number of new ANC and L&D clients		46,136
	By: Known positives at entry		1,375
	By: Number of new positives identified		3,395
	Sum of Positives Status disaggregates		4,770
	Required only for DREAMS Countries - By Number of new positives: <15		
	Required only for DREAMS Countries - By Number of new positives: 15-19		
	Required only for DREAMS Countries - By Number of new positives: 20-24		
	Required only for DREAMS Countries - By Number of new positives: 25+		

	Required only for DREAMS Countries - By Number of known positives: <15		
	Required only for DREAMS Countries - By Number of known positives: 15-19		
	Required only for DREAMS Countries - By Number of known positives: 20-24		
	Required only for DREAMS Countries - By Number of known positives: 25+		
	Required only for DREAMS Countries - Denominator: <15		
	Required only for DREAMS Countries - Denominator: <15-19		
	Required only for DREAMS Countries - Denominator: 20-24		
	Required only for DREAMS Countries - Denominator: 25+		
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)		236,792

	Number of new ANC and L&D clients		247,697
	By: Known positives at entry		3,292
	By: Number of new positives identified		8,992
	Sum of Positives Status disaggregates		12,284
	Required only for DREAMS countries - By known positives: <15		
	Required only for DREAMS countries - By known positives: 15-19		
	Required only for DREAMS countries - By known positives: 20-24		
	Required only for DREAMS countries - By known positives: 25+		
	Required only for DREAMS countries - By new positives: <15		
	Required only for DREAMS countries - By new positives: 15-19		
	Required only for DREAMS countries - By new positives: 20-24		
	Required only for DREAMS countries - By new positives: 25+		
	Required only for DREAMS countries - Denominator: <15		
	Required only for DREAMS countries - Denominator:		

	15-19		
	Required only for DREAMS countries - Denominator: 20-24		
	Required only for DREAMS countries - Denominator: 25+		
PMTCT_ARV_DSD	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	n/a	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery		5,292
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)		5,334
	Life-long ART (including Option B+)		
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy		2,285
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy		1,487

	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)		
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)		792
	Single-dose nevirapine (with or without tail)		18
	Sum of Regimen Type disaggregates		810
	Sum of New and Current disaggregates		3,772
PMTCT_ARV_TA	PMTCT_ARV_TA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (TA)	n/a	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery		12,459
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)		12,609

	Life-long ART (including Option B+)		
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy		6,733
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy		3,390
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)		757
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)		1,171
	Single-dose nevirapine (with or without tail)		21
	Sum of Regimen Type disaggregates		1,949
	Sum of New and Current disaggregates		10,123
PMTCT_FO_DSD	PMTCT_FO_DSD Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		3,779
	Number of HIV-exposed infants registered in the birth		4,194

	cohort at any time between 0 and 18 months of age (including transfer-ins)		
	HIV-infected: Linked to ART		8
	HIV-infected: Not linked to ART		0
	HIV-infected: Unknown link		
	HIV-uninfected: Not breastfeeding		150
	HIV-uninfected: Still breastfeeding		0
	HIV-uninfected: Breastfeeding status unknown		10
	Other: In care but no test done		0
	Other: Lost to follow-up		0
	Other: Died		0
	Other: Transferred out		0
PMTCT_FO_TA	PMTCT_FO_TA Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		7,740
	Number of HIV-exposed infants registered in the birth cohort at any time between 0 and 18 months of age (including transfer-ins)		9,537
	HIV-infected: Linked to ART		90

	HIV-infected: Not linked to ART		0
	HIV-infected: Unknown link		
	HIV-uninfected: Breastfeeding status unknown		7
	HIV-uninfected: Not breastfeeding		1,073
	HIV-uninfected: Still breastfeeding		533
	Other: Died		56
	Other: In care but no test done		139
	Other: Lost to follow-up		255
	Other: Transferred out		0
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.		8,629
	Total number of people in the target population		121,530
	Age/sex: 10-14 Male		0
	Age/sex: 15-19 Male		0
	Age/sex: 20-24 Male		400
	Age/sex: 25-49 Male		1,400

	Age/sex: 50+ Male		750
	Age/sex: 10-14 Female		0
	Age/sex: 15-19 Female		0
	Age/sex: 20-24 Female		100
	Age/sex: 25-49 Female		200
	Age/sex: 50+ Female		150
	Sum of Age/Sex disaggregates		3,000
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	n/a	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.		34,302
	Total number of people in the target population		138,246
	Age/sex: 10-14 Male		1,802
	Age/sex: 15-19 Male		5,000
	Age/sex: 20-24 Male		5,000
	Age/sex: 25-49 Male		0
	Age/sex: 50+ Male		0
	Age/sex: 10-14 Female		2,500
	Age/sex: 15-19 Female		10,000
	Age/sex: 20-24 Female		10,000
	Age/sex: 25-49 Female		0
	Age/sex: 50+ Female		0
	Sum of Age/Sex		34,302

	disaggregates		
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required		15,069
	Total estimated number of key population in the catchment area		41,371
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		11,246
	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence		

	and/or meet the minimum standards required)		
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		3,823
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key		23,716

	population in the catchment area)		
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months		84,917
	By Test Result: Negative		76,144
	By Test Result: Positive		8,775



	Sum of Test Result disaggregates		84,919
	Test Result by Age and Sex: Positive: <1 Male		0
	Test Result by Age and Sex: Positive: 1-4 Male		82
	Test Result by Age and Sex: Positive: 5-9 Male		39
	Test Result by Age and Sex: Positive: 10-14 Male		29
	Test Result by Age and Sex: Positive: 15-19 Male		20
	Test Result by Age and Sex: Positive: 20-24 Male		68
	Test Result by Age and Sex: Positive: 25-49 Male		369
	Test Result by Age and Sex: Positive: 50+ Male		59
	Test Result by Age and Sex: Positive: <1 Female		33
	Test Result by Age and Sex: Positive: 1-4 Female		640
	Test Result by Age and Sex: Positive: 5-9 Female		311
	Test Result by Age and Sex: Positive: 10-14 Female		246
	Test Result by Age and Sex: Positive: 15-19 Female		182
	Test Result by Age and Sex: Positive: 20-24 Female		575
	Test Result by Age and Sex: Positive: 25-49 Female		4,070
	Test Result by Age and Sex: Positive: 50+ Female		284

	Test Result by Age and Sex: Negative: <1 Male		42
	Test Result by Age and Sex: Negative: 1-4 Male		772
	Test Result by Age and Sex: Negative: 5-9 Male		416
	Test Result by Age and Sex: Negative: 10-14 Male		293
	Test Result by Age and Sex: Negative: 15-19 Male		240
	Test Result by Age and Sex: Negative: 20-24 Male		593
	Test Result by Age and Sex: Negative: 25-49 Male		3,161
	Test Result by Age and Sex: Negative: 50+ Male		492
	Test Result by Age and Sex: Negative: <1 Female		887
	Test Result by Age and Sex: Negative: 1-4 Female		6,542
	Test Result by Age and Sex: Negative: 5-9 Female		4,183
	Test Result by Age and Sex: Negative: 10-14 Female		3,389
	Test Result by Age and Sex: Negative: 15-19 Female		2,850
	Test Result by Age and Sex: Negative: 20-24 Female		5,969
	Test Result by Age and Sex: Negative: 25-49 Female		37,034
	Test Result by Age and Sex: Negative: 50+ Female		3,431
	Aggregated Age/sex - USE WITH HQ PERMISSION		1,028

	ONLY: <15 Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		8,828
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		10,869
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		64,179
	Sum of Aggregated Age/Sex <15		11,897
	Sum of Aggregated Age/Sex 15+		73,007
	Sum of Aggregated Age/Sex disaggregates		84,904
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		544
	Service Delivery Point by Result: Antenatal Clinic - Negative		14,558
	Service Delivery Point by Result: Labor & delivery - All results		2,670
	Service Delivery Point by Result: Labor & delivery - Positive		137
	Service Delivery Point by Result: Labor & delivery - Negative		2,533
	Service Delivery Point by		0

	Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		0
	Service Delivery Point by Result: Under 5 Clinic - Negative		0
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		0
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		0
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		0
	Service Delivery Point by Result: Tuberculosis – All results		0
	Service Delivery Point by Result: Tuberculosis - Positive		0
	Service Delivery Point by Result: Tuberculosis - Negative		0
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		0
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		0
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		0

	Service Delivery Point by Result: Outpatient Department – All Results		0
	Service Delivery Point by Result: Outpatient Department - Positive		0
	Service Delivery Point by Result: Outpatient Department - Negative		0
	Service Delivery Point by Result: Inpatient – All Results		0
	Service Delivery Point by Result: Inpatient - Positive		0
	Service Delivery Point by Result: Inpatient - Negative		0
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		0
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		0
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		0
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		0
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		0
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		0

	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		0
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		0
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive		0
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		0
	Service Delivery Point by Result: Mobile – All Results		7,643
	Service Delivery Point by Result: Mobile - Positive		1,591
	Service Delivery Point by Result: Mobile - Negative		6,052
	Service Delivery Point by Result: Home-based – All Results		0
	Service Delivery Point by Result: Home-based -		0

	Positive		
	Service Delivery Point by Result: Home-based - Negative		0
	Service Delivery Point by Result: Other – All Results		0
	Service Delivery Point by Result: Other - Positive		0
	Service Delivery Point by Result: Other - Negative		0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months		293,440
	By Test Result: Negative		277,022
	By Test Result: Positive		16,309
	Sum of Test Result disaggregates		293,331
	Test Result by Age and Sex: Positive: <1 Male		21
	Test Result by Age and Sex: Positive: 1-4 Male		104
	Test Result by Age and Sex: Positive: 5-9 Male		59
	Test Result by Age and Sex: Positive: 10-14 Male		41
	Test Result by Age and Sex: Positive: 15-19 Male		43
	Test Result by Age and Sex: Positive: 20-24 Male		175
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex:		149



	Positive: 50+ Male		
	Test Result by Age and Sex: Positive: <1 Female		125
	Test Result by Age and Sex: Positive: 1-4 Female		804
	Test Result by Age and Sex: Positive: 5-9 Female		548
	Test Result by Age and Sex: Positive: 10-14 Female		488
	Test Result by Age and Sex: Positive: 15-19 Female		573
	Test Result by Age and Sex: Positive: 20-24 Female		1,571
	Test Result by Age and Sex: Positive: 25-49 Female		7,650
	Test Result by Age and Sex: Positive: 50+ Female		829
	Test Result by Age and Sex: Negative: <1 Male		1,322
	Test Result by Age and Sex: Negative: 1-4 Male		3,381
	Test Result by Age and Sex: Negative: 5-9 Male		2,742
	Test Result by Age and Sex: Negative: 10-14 Male		2,029
	Test Result by Age and Sex: Negative: 15-19 Male		1,844
	Test Result by Age and Sex: Negative: 20-24 Male		4,002
	Test Result by Age and Sex: Negative: 25-49 Male		16,350
	Test Result by Age and Sex: Negative: 50+ Male		3,407
	Test Result by Age and Sex:		5,688

	Negative: <1 Female		
	Test Result by Age and Sex: Negative: 1-4 Female		20,983
	Test Result by Age and Sex: Negative: 5-9 Female		15,613
	Test Result by Age and Sex: Negative: 10-14 Female		14,477
	Test Result by Age and Sex: Negative: 15-19 Female		16,284
	Test Result by Age and Sex: Negative: 20-24 Female		30,333
	Test Result by Age and Sex: Negative: 25-49 Female		121,518
	Test Result by Age and Sex: Negative: 50+ Female		16,347
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		7,249
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		26,444
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		49,979
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		196,970
	Sum of Aggregated Age/Sex <15		57,228
	Sum of Aggregated Age/Sex 15+		223,414
	Sum of Aggregated Age/Sex disaggregates		280,642
	Service Delivery Point by		

	Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		3,888
	Service Delivery Point by Result: Antenatal Clinic - Negative		93,502
	Service Delivery Point by Result: Labor & delivery - All results		16,635
	Service Delivery Point by Result: Labor & delivery - Positive		861
	Service Delivery Point by Result: Labor & delivery - Negative		15,764
	Service Delivery Point by Result: Under 5 Clinic – All results		5,404
	Service Delivery Point by Result: Under 5 Clinic - Positive		225
	Service Delivery Point by Result: Under 5 Clinic - Negative		5,179
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		5,292
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		267
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		5,025

	Service Delivery Point by Result: Tuberculosis – All results		3,024
	Service Delivery Point by Result: Tuberculosis - Positive		272
	Service Delivery Point by Result: Tuberculosis - Negative		2,752
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		3,524
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		197
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		3,327
	Service Delivery Point by Result: Outpatient Department – All Results		19,169
	Service Delivery Point by Result: Outpatient Department - Positive		931
	Service Delivery Point by Result: Outpatient Department - Negative		18,238
	Service Delivery Point by Result: Inpatient – All Results		5,128
	Service Delivery Point by Result: Inpatient - Positive		233
	Service Delivery Point by Result: Inpatient - Negative		4,895
	Service Delivery Point by		1,621

	Result: HIV care and treatment clinic – All Results		
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		7
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		341
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		0
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		0
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		0
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		70
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		1,305
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - All		
	Service Delivery Point by Result: Voluntary Counseling		90

	& Testing (standalone) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Negative		1,956
	Service Delivery Point by Result: Mobile – All Results		8,138
	Service Delivery Point by Result: Mobile - Positive		389
	Service Delivery Point by Result: Mobile - Negative		7,749
	Service Delivery Point by Result: Home-based – All Results		3,076
	Service Delivery Point by Result: Home-based - Positive		133
	Service Delivery Point by Result: Home-based - Negative		2,943
	Service Delivery Point by Result: Other – All Results		761
	Service Delivery Point by Result: Other - Positive		21
	Service Delivery Point by Result: Other - Negative		740
	Test Result by Aggregated Age and Sex: Negative <15 Male		
	Test Result by Aggregated Age and Sex: Negative 15+ Male		5
	Test Result by Aggregated Age and Sex: Negative <15		98

	Female		
	Test Result by Aggregated Age and Sex: Negative 15+ Female		137
	Test Result by Aggregated Age and Sex: Positive <15 Male		0
	Test Result by Aggregated Age and Sex: Positive 15+ Male		0
	Test Result by Aggregated Age and Sex: Positive <15 Female		4
	Test Result by Aggregated Age and Sex: Positive 15+ Female		5
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		2,526
	Total number of registered new and relapsed TB cases, during the reporting period.		4,132
	Sex: Male		837
	Sex: Female		1,679
	Age: <1		91
	Age: 1-4		208
	Age: 5-9		204
	Age: 10-14		116

	Age 15-19		
	Age: 20+		1,225
	Status: Positive		1,214
	Status: Negative		1,309
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		5,938
	Total number of registered new and relapsed TB cases, during the reporting period.		8,762
	Age 15-19		
	Age: <1		138
	Age: 1-4		298
	Age: 10-14		466
	Age: 20+		3,313
	Age: 5-9		387
	Sex: Female		3,778
	Sex: Male		1,865
	Status: Negative		3,317
	Status: Positive		2,263
	GEND_GBV_DSD	Number of people receiving post-GBV care	
Age/Sex: <10 Male			
Age/Sex: 10-14 Male			
Age/Sex: 15-17 Male			
Age/Sex: 18-24 Male			
Age/Sex: 25+ Male			

	Age/Sex: <10 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	Age/Sex: 18-24 Female		
	Age/Sex: 25+ Female		
	Sum of Age/Sex Disaggregates		
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)		
	By type of service: Sexual Violence (Post-Rape Care)		
	By PEP service provision (related to sexual violence services provided)		
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria		10,784
	Age/Sex: <10 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20-24 Male		
	Age/Sex: 25+ Male		
	Age/Sex: <10 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20-24 Female		
	Age/Sex: 25+ Female		
	By Age: 0-9		
	By Age: 10-14		
	By Age: 15-19		
	By Age: 20-24		

	By Age: 25+			
	Sum of Age disaggregates			
GEND_NORM_TA	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria		18,999	
	Age/Sex: <10 Male		0	
	Age/Sex: 10-14 Male		500	
	Age/Sex: 15-19 Male		2,500	
	Age/Sex: 20-24 Male		1,250	
	Age/Sex: 25+ Male		2,500	
	Age/Sex: <10 Female		0	
	Age/Sex: 10-14 Female		750	
	Age/Sex: 15-19 Female		5,000	
	Age/Sex: 20-24 Female		2,500	
	Age/Sex: 25+ Female		5,000	
	By Age: 0-9			
	By Age: 10-14			
	By Age: 15-19			
	By Age: 20-24			
	By Age: 25+			
	Sum of Age disaggregates			
	OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services		5,094
		Age/Sex: <1 Male		36
Age/Sex: 1-4 Male			259	
Age/Sex: 5-9 Male			770	
Age/Sex: 10-14 Male			1,018	
Age/Sex: 15-17 Male			493	
Age/Sex: 18-24 Male			113	

	Age/Sex: 25+ Male		0
	Age/Sex: <1 Female		26
	Age/Sex: 1-4 Female		239
	Age/Sex: 5-9 Female		736
	Age/Sex: 10-14 Female		914
	Age/Sex: 15-17 Female		400
	Age/Sex: 18+ Female		
	Age/Sex: 18-24 Female		90
	Age/Sex: 25+ Female		0
	Sum of Age/Sex disaggregates		5,094
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS		6,583
	Age/Sex: <1 Male		47
	Age/Sex: 1-4 Male		335
	Age/Sex: 5-9 Male		994
	Age/Sex: 10-14 Male		1,317
	Age/Sex: 15-17 Male		635
	By: Age/sex: Male 18-24		147
	By: Age/sex: Male 25+		0
	Age/Sex: <1 Female		33
	Age/Sex: 1-4 Female		307
	Age/Sex: 5-9 Female		952
	Age/Sex: 10-14 Female		1,182
	Age/Sex: 15-17 Female		518
	By: Age/sex: 18-24 Female		116
	By: Age/sex: 25+ Female		0
	Sum of Age/Sex disaggregates		6,320
	Required only for DREAMS		



	countries - By service, age and sex: Education Support Female <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+		
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 1-4		



	Required only for DREAMS countries - By service, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver		



	Programs Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17		
	Required only for DREAMS countries - By service, age		

	and sex: Parenting/Caregiver Programs Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+		
	Required only for DREAMS		

	countries - By service, age and sex: Social Protection Male <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1		33
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-4		307



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 5-9		952
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14		1,182
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17		518
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24		116
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+		0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1		47
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-4		335
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 5-9		994
	Required only for DREAMS countries - By service, age and sex: Economic		1,317

	Strengthening Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Economic		635
	Strengthening Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic		147
	Strengthening Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic		0
	Strengthening Male 25+		
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS		650
	Age/Sex: <1 Male		0
	Age/Sex: 1-4 Male		0
	Age/Sex: 5-9 Male		0
	Age/Sex: 10-14 Male		25
	Age/Sex: 15-17 Male		25
	By age/sex: 18-24 Male		50
	By age/sex: 25+ Male		200
	Age/Sex: <1 Female		0
	Age/Sex: 1-4 Female		0
	Age/Sex: 5-9 Female		0
	Age/Sex: 10-14 Female		50
	Age/Sex: 15-17 Female		50
	By age/sex: 18-24 Female		50
	By age/sex: 25+ Female		200
	Sum of Age/Sex disaggregates		150



	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education		



	Support Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program		

	Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9		



	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14		



	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social		

	Protection Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social		
	Protection Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic		
	Strengthening Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic		
	Strengthening Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Economic		
	Strengthening Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Economic		
	Strengthening Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Economic		
	Strengthening Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Economic		
	Strengthening Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Economic		
	Strengthening Female 25+		
	Required only for DREAMS countries: By Service Area,		



	age and sex: Economic Strengthening Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4		
	Required only for DREAMS		

	countries: By Service Area, age and sex: Other Service Areas Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+		
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		22,966
	Age/sex: <1 Male		300
	Age/sex: 1-4 Male		600
	Age/sex: 5-9 Male		473
	Age/sex: 10-14 Male		326
	Age/sex: 15-19 Male		321
	Age/sex: 20-24 Male		866
	Age/sex: 25-49 Male		3,300
	Age/sex: 50+ Male		595

	Age/sex: <1 Female		749
	Age/sex: 1-4 Female		1,346
	Age/sex: 5-9 Female		1,476
	Age/sex: 10-14 Female		1,450
	Age/sex: 15-19 Female		1,557
	Age/sex: 20-24 Female		1,707
	Age/sex: 25-49 Female		6,668
	Age/sex: 50+ Female		1,224
	Sun of Age/Sex disaggregates		22,958
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates		
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		122,100
	Age/sex: <1 Male		1,984
	Age/sex: 1-4 Male		3,484
	Age/sex: 5-9 Male		2,717

	Age/sex: 10-14 Male		2,117
	Age/sex: 15-19 Male		1,895
	Age/sex: 20-24 Male		3,809
	Age/sex: 25-49 Male		14,835
	Age/sex: 50+ Male		2,944
	Age/sex: <1 Female		2,841
	Age/sex: 1-4 Female		6,624
	Age/sex: 5-9 Female		6,820
	Age/sex: 10-14 Female		6,209
	Age/sex: 15-19 Female		8,168
	Age/sex: 20-24 Female		11,791
	Age/sex: 25-49 Female		39,274
	Age/sex: 50+ Female		6,499
	Sum of Age/Sex disaggregates		122,011
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		0
	Sum of Aggregated Age/Sex disaggregates		0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of		11,425

	the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age/sex: <1 Male		137
	Age/sex: 1-4 Male		279
	Age/sex: 5-9 Male		225
	Age/sex: 10-14 Male		151
	Age/sex: 15-19 Male		148
	Age/sex: 20-24 Male		399
	Age/sex: 25-49 Male		1,505
	Age/sex: 50+ Male		276
	Age/sex: <1 Female		390
	Age/sex: 1-4 Female		713
	Age/sex: 5-9 Female		795
	Age/sex: 10-14 Female		774
	Age/sex: 15-19 Female		816
	Age/sex: 20-24 Female		871
	Age/sex: 25-49 Female		3,293
	Age/sex: 50+ Female		644
	Sum of Age/sex disaggregates		11,416
	Aggregated Age/sex: <15 Male		
	Aggregated Age/sex: 15+ Male		
	Aggregated Age/sex: <15 Female		
	Aggregated Age/sex: 15+ Female		
	Sum of Aggregated Age/sex disaggregates		
CARE_NEW_TA	Number of HIV-infected		20,541

	adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age/sex: <1 Female		414
	Age/sex: 1-4 Female		953
	Age/sex: 5-9 Female		1,021
	Age/sex: 10-14 Female		981
	Age/sex: 15-19 Female		1,139
	Age/sex: 20-24 Female		1,880
	Age/sex: 25-49 Female		6,647
	Age/sex: 50+ Female		1,116
	Age/sex: <1 Male		222
	Age/sex: 1-4 Male		456
	Age/sex: 5-9 Male		461
	Age/sex: 10-14 Male		278
	Age/sex: 15-19 Male		294
	Age/sex: 20-24 Male		721
	Age/sex: 25-49 Male		2,827
	Age/sex: 50+ Male		646
	Aggregated Age/sex: <15 Female		
	Aggregated Age/sex: <15 Male		
	Aggregated Age/sex: 15+ Female		
	Aggregated Age/sex: 15+ Male		
	Sum of Aggregated Age/sex		

	disaggregates		
	Sum of age/sex disaggregates		20,056
TB_IPT_TA	TB_IPT_TA Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
	The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period		0
	Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		0
	Age: 1-4		0
	Age: 5-9		0
	Age: 10-14		0
	Age: 15-19		0
	Age: 20+		0
	Sum of Age disaggregates		0
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15		0
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: 15+		0
	Sex: Male		0

	Sex: Female		0
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period		2,692
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period		4,309
	Age: <1		30
	Age: 1-4		82
	Age: 5-9		104
	Age: 10-14		167
	Age: 15-19		298
	Age: 20+		1,415
	Sum of Age disaggregates		2,096
	Aggregated Age: <15		0
	Aggregated Age: 15+		0
	Sum of Aggregated Age disaggregates		0
	Male		663
	Female		1,496
	Sum of Sex disaggregates		2,159
	Known HIV-positive		428
	Newly tested		
	Sum of Test Status		428

	disaggregates		
	Timeliness: Art initiation <8 weeks of start of TB treatment		706
	Timeliness: Art initiation >8 weeks of start of TB treatment		200
TB_OUTCOME_DSD	TB_OUTCOME_DSD TB treatment outcomes among registered new and relapsed TB cases who are HIV-positive	n/a	
	Aggregated outcomes of TB treatment among registered new and relapsed TB cases who are HIV-positive in the treatment cohort		2,149
	The total number of registered new and relapsed TB cases who are HIV-positive registered in the treatment cohort		4,136
	Outcome by Age: Cured <1		
	Outcome by Age: Cured 1-4		
	Outcome by Age: Cured 5-9		
	Outcome by Age: Cured 10-14		
	Outcome by Age: Cured: 15-19		
	Outcome by Age: Cured 20+		
	Outcome by Age: Treatment Complete <1		
	Outcome by Age: Treatment Complete 1-4		



	Outcome by Age: Treatment Complete 5-9		
	Outcome by Age: Treatment Complete 10-14		
	Outcome by Age: Treatment Complete 15-19		
	Outcome by Age: Treatment Complete 20+		
	Outcome by Age: Treatment Failed <1		
	Outcome by Age: Treatment Failed 1-4		
	Outcome by Age: Treatment Failed 5-9		
	Outcome by Age: Treatment Failed 10-14		
	Outcome by Age: Treatment Failed 15-19		
	Outcome by Age: Treatment Failed 20+		
	Outcome by Age: Died <1		
	Outcome by Age: Died 1-4		
	Outcome by Age: Died 5-9		
	Outcome by Age: Died 10-14		
	Outcome by Age: Died 15-19		
	Outcome by Age: Died 20+		
	Outcome by Age: Lost to Follow-up <1		
	Outcome by Age: Lost to Follow-up 1-4		
	Outcome by Age: Lost to Follow-up 5-9		
	Outcome by Age: Lost to Follow-up 10-14		



	Outcome by Age: Lost to Follow-up 15-19		
	Outcome by Age: Lost to Follow-up 20+		
	Outcome by Age: Not Evaluated <1		
	Outcome by Age: Not Evaluated 1-4		
	Outcome by Age: Not Evaluated 5-9		
	Outcome by Age: Not Evaluated 10-14		
	Outcome by Age: Not Evaluated 15-19		
	Outcome by Age: Not Evaluated 20+		0
	Outcome by Sex: Treatment Complete Female		
	Outcome by Sex: Treatment Complete Male		
	Outcome by Sex: Cured Female		
	Outcome by Sex: Cured Male		
	Outcome by Sex: Treatment failed Female		
	Outcome by Sex: Treatment failed Male		
	Outcome by Sex: Died Female		
	Outcome by Sex: Died Male		
	Outcome by Sex: Lost to Follow-up Female		
	Outcome by Sex: Lost to		

	Follow-up Male		
	Outcome by Sex: Not Evaluated Female		
	Outcome by Sex: Not Evaluated Male		
TB_OUTCOME_TA	TB_OUTCOME_TA TB treatment outcomes among registered new and relapsed TB cases who are HIV-positive	n/a	
	Aggregated outcomes of TB treatment among registered new and relapsed TB cases who are HIV-positive in the treatment cohort		3,532
	The total number of registered new and relapsed TB cases who are HIV-positive registered in the treatment cohort		5,349
	Outcome by Age: Cured <1		8
	Outcome by Age: Cured 1-4		17
	Outcome by Age: Cured 5-9		28
	Outcome by Age: Cured 10-14		40
	Outcome by Age: Cured 15-19		74
	Outcome by Age: Cured 20+		451
	Outcome by Sex: Cured Female		
	Outcome by Sex: Cured Male		
	Outcome by Age: Treatment Complete <1		15

	Outcome by Age: Treatment Complete 1-4		28
	Outcome by Age: Treatment Complete 5-9		28
	Outcome by Age: Treatment Complete 10-14		40
	Outcome by Age: Treatment Complete 15-19		73
	Outcome by Age: Treatment Complete 20+		398
	Outcome by Sex: Treatment Complete Female		332
	Outcome by Sex: Treatment Complete Male		235
	Outcome by Age: Treatment Failed <1		0
	Outcome by Age: Treatment Failed 1-4		0
	Outcome by Age: Treatment Failed 5-9		0
	Outcome by Age: Treatment Failed 10-14		6
	Outcome by Age: Treatment Failed 15-19		24
	Outcome by Age: Treatment Failed 20+		61
	Outcome by Sex: Treatment Failed Female		
	Outcome by Sex: Treatment Failed Male		
	Outcome by Age: Died <1		0
	Outcome by Age: Died 1-4		0
	Outcome by Age: Died 5-9		0
	Outcome by Age: Died 10-14		0

	Outcome by Age: Died 15-19		0
	Outcome by Age: Died 20+		34
	Outcome by Sex: Died Female		
	Outcome by Sex: Died Male		
	Outcome by Age: Lost to Follow-up <1		0
	Outcome by Age: Lost to Follow-up 1-4		0
	Outcome by Age: Lost to Follow-up 5-9		6
	Outcome by Age: Lost to Follow-up 10-14		13
	Outcome by Age: Lost to Follow-up 15-19		21
	Outcome by Age: Lost to Follow-up 20+		123
	Outcome by Sex: Lost to Follow-up Female		
	Outcome by Sex: Lost to Follow-up Male		
	Outcome by Age: Not Evaluated <1		0
	Outcome by Age: Not Evaluated 1-4		0
	Outcome by Age: Not Evaluated 5-9		0
	Outcome by Age: Not Evaluated 10-14		0
	Outcome by Age: Not Evaluated 15-19		3
	Outcome by Age: Not Evaluated 20+		51
	Outcome by Sex: Not		

	Evaluated Female		
	Outcome by Sex: Not Evaluated Male		
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		10,152
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		22,966
	Age: <1		50
	Age: 1-4		90
	Age: 5-9		114
	Age: 10-14		97
	Age: 15-19		92
	Age: 20+		368
	Sum of Age disaggregates		811
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		
	Sum of Aggregated Age		

	disaggregates		
	Sex: Male		129
	Sex: Female		3,090
	Sum of Sex disaggregates		3,219
TB_SCREEN_TA	TB_SCREEN_TA Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		15,441
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		122,100
	Age: <1		88
	Age: 1-4		175
	Age: 5-9		244
	Age: 10-14		451
	Age: 15-19		530
	Age: 20+		7,553
	Sum of Age disaggregates		9,041
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		0
	Aggregated Age - USE WITH HQ PERMISSION ONLY:		0

	15+		
	Sum of Aggregated Age disaggregates		0
	Sex: Female		6,813
	Sex: Male		1,962
	Sum of Sex disaggregates		8,775
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period		4,068
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)		
	By infants who received a virologic test within 2 months of birth		3,481
	By infants who received their first virologic HIV test between 2 and 12 months of age		587
	Sum of Infant Age disaggregates		4,068
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result		163

	within 2 months of birth		
	Number of infants with a positive virological test result within 12 months of birth		37
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period		11,287
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)		
	By infants who received a virologic test within 2 months of birth		9,112
	By infants who received their first virologic HIV test between 2 and 12 months of age		1,993
	Sum of Infant Age disaggregates		11,105
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		402
	Number of infants with a positive virological test result		301

	within 12 months of birth		
PMTCT_CTX_DSD	PMTCT_CTX_DSD Percentage of infants born to HIV-positive pregnant women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth	n/a	
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth within the reporting period		3,688
	Number of HIV-positive pregnant women identified in the reporting period (include known HIV- positive at entry)		
PMTCT_CTX_TA	PMTCT_CTX_TA Percentage of infants born to HIV-positive pregnant women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth	n/a	
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth within the reporting period		12,138
	Number of HIV-positive pregnant women identified in the reporting period (include known HIV- positive at entry)		
CARE_COMM_DSD	Number of HIV-infected		1,328

	adults and children receiving care and support services outside of the health facility		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20-24 Male		
	Age/Sex: 25-49 Male		
	Age/Sex: 50+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20-24 Female		
	Age/Sex: 25-49 Female		
	Age/Sex: 50+ Female		
CARE_COMM_TA	Number of HIV-infected adults and children receiving care and support services outside of the health facility		4,946
	Age/Sex: <1 Female		0
	Age/Sex: <1 Male		0
	Age/Sex: 1-4 Female		0
	Age/Sex: 1-4 Male		0
	Age/Sex: 10-14 Female		250
	Age/Sex: 10-14 Male		250
	Age/Sex: 15-19 Female		512
	Age/Sex: 15-19 Male		258
	Age/Sex: 20-24 Female		525

	Age/Sex: 20-24 Male		264
	Age/Sex: 25-49 Female		1,650
	Age/Sex: 25-49 Male		868
	Age/Sex: 5-9 Female		0
	Age/Sex: 5-9 Male		0
	Age/Sex: 50+ Female		228
	Age/Sex: 50+ Male		195
	Number of adults and children receiving antiretroviral therapy (ART)		19,546
	Age/Sex: <1 Male		269
	Age/Sex: 1-4 Male		394
	Age/Sex: 5-14 Male		316
	Age/Sex: 15-19 Male		507
	Age/Sex: 20+ Male		3,331
	Age/Sex: <1 Female		864
	Age/Sex: 1-4 Female		1,483
	Age/Sex: 5-14 Female		2,802
	Age/Sex: 15-19 Female		2,019
	Age/Sex: 20+ Female		7,405
	Aggregated Age/Sex: <1 Male		0
	Aggregated Age/Sex: <1 Female		0
	Aggregated Age/Sex: 15+ Male		0
	Aggregated Age/Sex: 1-14 Female		0
	Aggregated Age/Sex: 15+ Female		0
	Sum of Aggregated Age/Sex <15		
	Sum of Aggregated Age/Sex		0
TX_CURR_DSD			

	15+		
	Sum of Aggregated Age/Sex disaggregates		0
	Aggregated Age/Sex: 1-14 Male		0
	Sum of Aggregated Age/Sex (<1 and 1-14) <15		0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)		108,220
	Age/Sex: <1 Male		813
	Age/Sex: 1-4 Male		2,194
	Age/Sex: 5-14 Male		1,953
	Age/Sex: 15-19 Male		2,085
	Age/Sex: 20+ Male		22,788
	Age/Sex: <1 Female		2,861
	Age/Sex: 1-4 Female		5,134
	Age/Sex: 5-14 Female		10,803
	Age/Sex: 15-19 Female		8,146
	Age/Sex: 20+ Female		51,303
	Sum of Age/Sex disaggregations		108,080
	Aggregated Age/Sex: <1 Male		
	Aggregated Age/Sex: <1 Female		1
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male		
	Aggregated Age/Sex: 1-14 Female		
Aggregated Age/Sex: 15+			

	Female		
	Sum of Aggregated Age/Sex <15		
	Sum of Aggregated Age/Sex 15+		
	Sum of Aggregated Age/Sex disaggregates		
	Sum of Aggregated Age/Sex (<1 and 1-14) <15		1
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)		9,006
	By Age/Sex: <1 Male		111
	By Age/Sex: 1-4 Male		174
	By Age/Sex: 5-9 Male		232
	By Age/Sex: 10-14 Male		70
	By Age/Sex: 15-19 Male		117
	By Age/Sex: 20-24 Male		332
	By Age/Sex: 25-49 Male		1,379
	By Age/Sex: 50+ Male		221
	By Age/Sex: <1 Female		358
	By Age/Sex: 1-4 Female		559
	By Age/Sex: 5-9 Female		657
	By Age/Sex: 10-14 Female		624
	By Age/Sex: 15-19 Female		530
	By Age/Sex: 20-24 Female		529
	By Age/Sex: 25-49 Female		2,733
	By Age/Sex: 50+ Female		350
	Sum of Age/Sex disaggregates		8,976
	Aggregated Grouping by Age: <1 Male		
	Aggregated Grouping by		

	Age/Sex: 1-14 Male		
	Aggregated Grouping by Age/Sex: 15+ Male		
	Aggregated Grouping by Age/Sex: <1 Female		
	Aggregated Grouping by Age/Sex: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates		
	Pregnancy status		
	Breastfeeding status		
	Aggregated Grouping by Age/Sex: 1-14 Female		
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)		20,570
	By Age/Sex: <1 Male		197
	By Age/Sex: 1-4 Male		282
	By Age/Sex: 5-9 Male		605
	By Age/Sex: 10-14 Male		192
	By Age/Sex: 15-19 Male		267
	By Age/Sex: 20-24 Male		635
	By Age/Sex: 25-49 Male		2,869
	By Age/Sex: 50+ Male		555
	By Age/Sex: <1 Female		627
	By Age/Sex: 1-4 Female		1,214
	By Age/Sex: 5-9 Female		1,181
	By Age/Sex: 10-14 Female		1,209
	By Age/Sex: 15-19 Female		977
	By Age/Sex: 20-24 Female		1,358
	By Age/Sex: 25-49 Female		7,135
	By Age/Sex: 50+ Female		1,164
	Sum of Age/Sex		20,467

	disaggregates		
	Aggregated Grouping by Age: <1 Male		
	Aggregated Grouping by Age/Sex: 1-14 Male		
	Aggregated Grouping by Age/Sex: 15+ Male		
	Aggregated Grouping by Age: <1 Female		
	Aggregated Grouping by Age/Sex: 1-14 Female		
	Aggregated Grouping by Age/Sex: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates		
	Pregnancy status		2,168
	Breastfeeding status		67
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART		4,869
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		5,409
	Age/Sex: <5 Male		489

	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		240
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		100
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		1,462
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		240
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		197
	Age/Sex: 15-19 Female		100

	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		2,032
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		537
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		272
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning		104

	of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		1,619
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		272
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		213
	Age/Sex: 15-19 Female		104

	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		2,270
	Numerator by Status: Pregnant		
	Numerator by Status: Breastfeeding		
	Denominator by Status: Pregnant		
	Denominator by Status: Breastfeeding		
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART		26,788

	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		61,893
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		1,587
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		1,181
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		645
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		5,784
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at		1,699

	12 months after initiating ART)		
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		2,164
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		1,260
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		12,316
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		3,214
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,		2,373



	including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		1,098
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		14,010
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		3,195
	Age/Sex: 5-14 Female (Denominator: Total number		4,090

	of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		2,169
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		31,447
	Numerator by Status: Pregnant		1,197
	Numerator by Status: Breastfeeding		105
	Denominator by Status: Pregnant		1,220
	Denominator by Status: Breastfeeding		78

TX_VIRAL_DSD	TX_VIRAL_DSD Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months		5,926
	Number of adults and children on ART at least 6 months whose medical records were reviewed		11,858
	Age/Sex: <1 Male		181
	Age/Sex: 1-4 Male		360
	Age/Sex: 5-14 Male		299
	Age/Sex: 15-19 Male		119
	Age/Sex: 20+ Male		1,768
	Age/Sex: <1 Female		473
	Age/Sex: 1-4 Female		299
	Age/Sex: 5-14 Female		360
	Age/Sex: 15-19 Female		119
	Age/Sex: 20+ Female		1,942
	Results Category: Undetectable		
Results Category: Detectable			
TX_VIRAL_TA	TX_VIRAL_TA Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record		1,543

	within the past 12 months.		
	Number of adults and children on ART at least 6 months whose medical records were reviewed.		3,585
	Age/Sex: <1 Male		0
	Age/Sex: 1-4 Male		1
	Age/Sex: 5-14 Male		1
	Age/Sex: 15-19 Male		1
	Age/Sex: 20+Male		20
	Age/Sex: <1 Female		2
	Age/Ses: 1-4 Female		1
	Age/Sex: 5-14 Female		1
	Age/Sex: 15-19 Female		3
	Age/Sex: 20+ Female		30
	Result Category: Undetectable		24
	Result Category: Detectable		36
LAB_ACC_TA	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		12
LAB_CAP_TA	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests		800
	By clinical laboratories		770

	By Point-of-care testing sites		30
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program		
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program		150
	CD4: Number of laboratories that participate in this PT program		160
	CD4: Number of laboratories that perform this testing		170
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program		3
	Early infant diagnostics: Number of laboratories that participate in this PT program		3
	Early infant diagnostics: Number of laboratories that perform this testing		3
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program		400

	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program		500
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing		800
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program		4
	HIV viral load: Number of laboratories that participate in this PT program		4
	HIV viral load: Number of laboratories that perform this testing		4
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		0
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing		0
	TB diagnostics (Xpert MTB/RIF): Number of		

	laboratories that achieve acceptable successful passing criteria in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing		
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program		0
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		0
TX_UNDETECT_DSD	TX_UNDETECT_DSD Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		5,334

	Number of viral load tests performed from adults and children on ART within the current reporting period		5,927
	Age/Sex: <1 Male		163
	Age/Sex: 1-4 Male		319
	Age/Sex: 5-14 Male		269
	Age/Sex: 15-19 Male		104
	Age/Sex: 20+ Male		1,590
	Age/Sex: <1 Female		427
	Age/Sex: 1-4 Female		269
	Age/Sex: 5-14 Female		319
	Age/Sex: 15-19 Female		104
	Age/Sex: 20+ Female		1,760
	Pregnant		
	Breastfeeding		
	Test indication: Routine monitoring		
	Test indication: Targeted monitoring		
TX_UNDETECT_TA	TX_UNDETECT_TA Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		2,081
	Number of viral load tests performed from adults and children on ART within the current reporting period		2,233

	Age/Sex: <1 Female		18
	Age/Sex: <1 Male		15
	Age/Sex: 1-4 Female		7
	Age/Sex: 1-4 Male		5
	Age/Sex: 15-19 Female		12
	Age/Sex: 15-19 Male		10
	Age/Sex: 20+ Female		400
	Age/Sex: 20+ Male		263
	Age/Sex: 5-14 Female		7
	Age/Sex: 5-14 Male		13
	Breastfeeding		68
	Pregnant		100
	Test indication: Routine monitoring		700
	Test indication: Targeted monitoring		50

## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
12937	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	342,179
13003	NACC	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13167	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	0
13257	Cameroon Baptist Convention Health Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	460,872
13799	Global Health Systems Solutions	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,487,062
14092	Management Sciences for	NGO	U.S. Agency for International	GHP-State	1,273,000

	Health		Development		
14118	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
14127	WHO/AFRO	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	140,000
14175	United Nations Children's Fund	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	65,000
14659	Directorate of Family Health, Ministry of Health	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
16743	Care International	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	2,142,966
16744	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	548,715
16816	Elizabeth Glaser	NGO	U.S. Department	GHP-State	425,600



	Pediatric AIDS Foundation		of Health and Human Services/Centers for Disease Control and Prevention		
17336	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	366,572
17361	Cameroon Baptist Convention Health Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	13,075,131
17362	Safe Blood for Africa Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	75,000
17364	Population Services International	NGO	U.S. Department of Defense	GHP-State	381,700
17365	Metabiota	Private Contractor	U.S. Department of Defense	GHP-State	1,221,018
18049	FHI 360	NGO	U.S. Agency for International Development	GHP-State	700,000
18062	NACC	Implementing	U.S. Department	GHP-State	666,000



		Agency	of Health and Human Services/Centers for Disease Control and Prevention		
18080	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	265,000



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 12937</b>	<b>Mechanism Name: Capacity Strengthening for Peace Corps Volunteers and Counterparts</b>
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 342,179</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	342,179

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Education	342,179
-----------	---------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 12937</b>
----------------------------



<b>Mechanism Name:</b>	<b>Capacity Strengthening for Peace Corps Volunteers and Counterparts</b>		
<b>Prime Partner Name:</b>	<b>U.S. Peace Corps</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	125,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	62,576	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	154,603	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13003</b>	<b>Mechanism Name: Strengthening the capacity of the National AIDS Control Committee to ensure prevention of HIV in health-care settings</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: NACC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

Custom



(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13003		
<b>Mechanism Name:</b>	Strengthening the capacity of the National AIDS Control Committee to ensure prevention of HIV in health-care settings		
<b>Prime Partner Name:</b>	NACC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

**Implementing Mechanism Indicator Information**



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 13167</b>	<b>Mechanism Name: Supplies and Reagents for CDC-NACC CoAg</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 3,865,930</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 13167</b>
----------------------------



<b>Mechanism Name:</b> Supplies and Reagents for CDC-NACC CoAg			
<b>Prime Partner Name:</b> Partnership for Supply Chain Management			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13257</b>	<b>Mechanism Name: Implementation of PMTCT CoAg1</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Cameroon Baptist Convention Health Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 460,872</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	460,872

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13257			
<b>Mechanism Name:</b> Implementation of PMTCT CoAg1			
<b>Prime Partner Name:</b> Cameroon Baptist Convention Health Board			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	30,522	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	4,164	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	13,254	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HLAB	26,407	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	27,973	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	27,349	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	326,869	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	4,334	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13799</b>	<b>Mechanism Name: GHSS-Strengthening Public Health Laboratory Systems in Cameroon</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Health Systems Solutions	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,487,062</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,487,062



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13799		
<b>Mechanism Name:</b>	GHSS-Strengthening Public Health Laboratory Systems in Cameroon		
<b>Prime Partner Name:</b>	Global Health Systems Solutions		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	138,279	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	594,825	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	453,958	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14092</b>	<b>Mechanism Name: Systems for Improved Access to Pharmaceuticals and Services Program (SIAPS)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,273,000</b>	
<b>Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,273,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Renovation	150,000
Motor Vehicles: Leased	22,500
Human Resources for Health	297,050

## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b>	14092		
<b>Mechanism Name:</b>	Systems for Improved Access to Pharmaceuticals and Services		
<b>Prime Partner Name:</b>	Program (SIAPS)		
	Management Sciences for Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	229,140	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	269,170	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	76,380	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	318,250	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	380,060	0

## Implementing Mechanism Indicator Information



(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14118</b>	<b>Mechanism Name: Strengthening Clinical Laboratory Workforce</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 100,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	100,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
----------------------------	---------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	<b>14118</b>
<b>Mechanism Name:</b>	<b>Strengthening Clinical Laboratory Workforce</b>



<b>Prime Partner Name:</b> African Society for Laboratory Medicine			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14127</b>		<b>Mechanism Name: WHO Cameroon</b>	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: WHO/AFRO			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	

<b>Total All Funding Sources: 140,000</b>	
<b>Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	140,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
----------------------------	--------



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 14127			
<b>Mechanism Name:</b> WHO Cameroon			
<b>Prime Partner Name:</b> WHO/AFRO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	17,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	14,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	87,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	21,000	0

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID:</b> 14175	<b>Mechanism Name:</b> Partnerships for elimination of MTCT
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 65,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	65,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	14175		
<b>Mechanism Name:</b>	Partnerships for elimination of MTCT		
<b>Prime Partner Name:</b>	United Nations Children's Fund		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	10,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	PDTX	55,000	0
-----------	------	--------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14659</b>	<b>Mechanism Name: Integration of comprehensive PMTCT activities into MCH services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Directorate of Family Health, Ministry of Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 300,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	300,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	14659		
<b>Mechanism Name:</b>	Integration of comprehensive PMTCT activities into MCH services		
<b>Prime Partner Name:</b>	Directorate of Family Health, Ministry of Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	37,500	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	15,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	146,250	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	101,250	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16743</b>	<b>Mechanism Name: Continuum of Prevention, Care, and Treatment for HIV/AIDS with MARPs in Cameroon (CHAMP)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Care International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,142,966</b>	
<b>Applied Pipeline Amount: 700,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,479,681
GHP-USAID	663,285

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Key Populations: FSW	1,000,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Key Populations: MSM and TG	800,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current

	PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Food and Nutrition: Policy, Tools, and Service Delivery	149,000
Human Resources for Health	450,000
Food and Nutrition: Commodities	250,000
Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	62,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Condom programming	120,000

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16743		
<b>Mechanism Name:</b>	Continuum of Prevention, Care, and Treatment for HIV/AIDS with MARPs in Cameroon (CHAMP)		
<b>Prime Partner Name:</b>	Care International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	650,084	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	342,875	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	64,288	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	85,719	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	1,000,000	0

### Implementing Mechanism Indicator Information

(No data provided.)



### Implementing Mechanism Details

<b>Mechanism ID: 16744</b>	<b>Mechanism Name: OVC care and support</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 548,715</b>	
<b>Applied Pipeline Amount: 395,030</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	548,715

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	182,495
Economic Strengthening	258,963
Gender: Gender Equality	371,200
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

### Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 16744			
<b>Mechanism Name:</b> OVC care and support			
<b>Prime Partner Name:</b> Catholic Relief Services			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	548,715	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16816</b>	<b>Mechanism Name: Technical Assistance support in assessing HIV service delivery in Cameroon</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 425,600</b>	
<b>Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	425,600

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

Human Resources for Health	206,000
----------------------------	---------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16816		
<b>Mechanism Name:</b>	Technical Assistance support in assessing HIV service delivery in Cameroon		
<b>Prime Partner Name:</b>	Elizabeth Glaser Pediatric AIDS Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	125,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	10,600	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	290,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17336</b>	<b>Mechanism Name: Columbia ICAP 2014 CDC HQ mech</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 366,572</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	366,572

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17336			
<b>Mechanism Name:</b> Columbia ICAP 2014 CDC HQ mech			
<b>Prime Partner Name:</b> Columbia University			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	306,572	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	60,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17361</b>	<b>Mechanism Name: CBCHB - PMTCT-ART Center-Littoral 2015</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Cameroon Baptist Convention Health Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 13,075,131</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	13,075,131

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,420,738
----------------------------	-----------

### Key Issues



(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17361			
<b>Mechanism Name:</b> CBCHB - PMTCT-ART Center-Littoral 2015			
<b>Prime Partner Name:</b> Cameroon Baptist Convention Health Board			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	944,592	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	116,523	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	685,780	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	1,532,222	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	790,297	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	8,799,335	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	206,382	0

**Implementing Mechanism Indicator Information**



(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17362</b>	<b>Mechanism Name: Safe Blood for Africa CDC 2015</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Safe Blood for Africa Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 75,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	75,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
----------------------------	--------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 17362
<b>Mechanism Name:</b> Safe Blood for Africa CDC 2015



<b>Prime Partner Name: Safe Blood for Africa Foundation</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	75,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17364</b>	<b>Mechanism Name: Prevention activities with Cameroon Military</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 381,700</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	381,700

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Condom programming	7,000
Human Resources for Health	10,000
Water	2,500



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 17364			
<b>Mechanism Name:</b> Prevention activities with Cameroon Military			
<b>Prime Partner Name:</b> Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	9,100	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	12,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	96,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	14,900	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	249,700	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

## Implementing Mechanism Indicator Information

(No data provided.)



### Implementing Mechanism Details

Mechanism ID: 17365	Mechanism Name: Strengthening Lab & MTCT Services in the military
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Metabiota	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,221,018	
Applied Pipeline Amount: 0	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,221,018

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
----------------------------	--------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 17365 <b>Mechanism Name:</b> Strengthening Lab & MTCT Services in the military <b>Prime Partner Name:</b> Metabiota			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Care	HBHC	242,282	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	21,962	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	25,662	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	1,297	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	81,935	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	39,938	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	807,942	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

## Implementing Mechanism Indicator Information



(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18049</b>	<b>Mechanism Name: LINKAGES</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 700,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	700,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18049		
<b>Mechanism Name:</b>	LINKAGES		
<b>Prime Partner Name:</b>	FHI 360		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HBHC	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	500,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18062</b>	<b>Mechanism Name: Strengthening the Capacity of the National AIDS Control Committee to Ensure Prevention of HIV in Health Care Settings</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: NACC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 666,000</b>	
<b>Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	666,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)



Human Resources for Health	40,000
----------------------------	--------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18062		
<b>Mechanism Name:</b>	Strengthening the Capacity of the National AIDS Control Committee to Ensure Prevention of HIV in Health Care Settings		
<b>Prime Partner Name:</b>	NACC		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	207,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	10,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	125,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	224,000	0

### Implementing Mechanism Indicator Information

(No data provided.)



### Implementing Mechanism Details

<b>Mechanism ID: 18080</b>	<b>Mechanism Name: ICAP - PMTCT-ART Center-Littoral 2015</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 265,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	265,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18080		
<b>Mechanism Name:</b>	ICAP - PMTCT-ART Center-Littoral 2015		
<b>Prime Partner Name:</b>	Columbia University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HBHC	28,992	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	2,660	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	6,524	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	3,765	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	17,471	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	200,878	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	4,710	0

### Implementing Mechanism Indicator Information

(No data provided.)



**Agency Information - Costs of Doing Business**  
**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services			0	0	0
ICASS			168,089	168,089	0
Indirect Costs			0	0	0
Institutional Contractors				0	0
Management Meetings/Professional Development			9,038	9,038	0
Non-ICASS Administrative Costs			70,930	70,930	0
Staff Program Travel		0	37,715	37,715	0
USG Staff Salaries and Benefits			550,943	550,943	30,000
<b>Total</b>	<b>0</b>	<b>0</b>	<b>836,715</b>	<b>836,715</b>	<b>30,000</b>

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		0		0	25,000



Computers/IT Services		5,000		5,000	0
ICASS		37,149		37,149	0
Management Meetings/Professional Development		6,000		6,000	0
Staff Program Travel		11,000		11,000	15,000
USG Staff Salaries and Benefits		79,000		79,000	0
<b>Total</b>	<b>0</b>	<b>138,149</b>	<b>0</b>	<b>138,149</b>	<b>40,000</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		40,000		40,000	0
Computers/IT Services		184,200		184,200	0
ICASS		1,482,398		1,482,398	0
Institutional Contractors		298,500		298,500	0
Management Meetings/Professional Development		20,000		20,000	0
Non-ICASS Administrative Costs		680,402		680,402	0
Peace Corps Volunteer Costs		30,000		30,000	0



Staff Program Travel		251,278		251,278	0
USG Staff Salaries and Benefits	575,119	1,372,890		1,948,009	0
<b>Total</b>	<b>575,119</b>	<b>4,359,668</b>	<b>0</b>	<b>4,934,787</b>	<b>0</b>

### U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		5,000		5,000	0
ICASS		50,000		50,000	0
Institutional Contractors		24,000		24,000	0
Management Meetings/Professional Development		30,000		30,000	0
Non-ICASS Administrative Costs		103,000		103,000	0
Peace Corps Volunteer Costs				0	0
Staff Program Travel		38,000		38,000	0
USG Staff Salaries and Benefits		70,000		70,000	0
<b>Total</b>	<b>0</b>	<b>320,000</b>	<b>0</b>	<b>320,000</b>	<b>0</b>

### U.S. Peace Corps



Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Non-ICASS Administrative Costs		177,311		177,311	0
Peace Corps Volunteer Costs		332,140		332,140	0
Staff Program Travel		41,257		41,257	0
USG Staff Salaries and Benefits		102,866		102,866	0
<b>Total</b>	<b>0</b>	<b>653,574</b>	<b>0</b>	<b>653,574</b>	<b>0</b>